Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marta Krásenská"'
Autor:
Rudolf Nenutil, Tomáš Kazda, Miloš Holánek, Iveta Selingerová, Katarína Petráková, Markéta Palácová, Rostislav Vyzula, Ondřej Bílek, Marta Krásenská, Mária Zvaríková
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 32(Supplementum2)
Background Mutations in the BRCA1 and BRCA2 genes are associated with a high risk of developing breast cancer. Tumors arising from this mutation are expected to be more sensitive to platinum-based drugs. The role of platinum-based drugs in systemic n
Autor:
Miloš Holánek, Markéta Palácová, Katarína Petráková, Marta Krásenská, Regina Demlová, Dalibor Valík
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 29
Adjuvant treatment with aromatase inhibitors improves outcomes in postmenopausal women with hormone-sensitive early breast cancer; however, they should not be used in premenopausal women. Menopausal status is the most important factor in the choice o
Autor:
Marta Krásenská
Publikováno v:
Klinicka onkologie. 29:3S39-3S49
Background The third generation aromatase inhibitors (anastrozole, letrozole, exemestane) have become standard endocrine treatment for postmenopausal estrogen receptor - positive breast cancers in all settings (neoadjuvant, adjuvant, metastatic breas